Related Experiment Video
Updated: Aug 21, 2026

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages
Published on: June 23, 2013
PRDM5 regulates ASK1 transcription to affect macrophage inflammation, lipid accumulation and apoptosis progression
Mengchen Sun1, Han Sun1, Hanzheng Wang2
1Qingdao Medical College, Qingdao University, Qingdao, 266071, China; Department of Cardiology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, 264000, China.
Background:
Atherosclerotic cardiovascular disease (ASCVD) has shared genetic susceptibility across various vascular lesions. Identification of common pathogenic factors for multi-territorial atherosclerosis is urgently required. We hypothesize that PR domain zinc finger protein 5 (PRDM5) acts as a shared pathogenic regulator to facilitate systemic atherosclerotic lesions by modulating monocyte-macrophage function.
Methods:
Multi-trait genome-wide association studies (GWAS) datasets were analyzed via genomic structural equation modeling (Genomic SEM) to uncover shared risk loci underlying ASCVD. Transcriptome-wide association study (TWAS) was performed in CD14+ monocytes to prioritize candidate genes. PRDM5 expression was validated in clinical peripheral blood monocytes and atherosclerotic plaques. Cellular functional assays, chromatin Immunoprecipitation quantitative real-time PCR (ChIP-qPCR), dual-luciferase reporter assay and molecular docking were combined to decipher downstream signaling and ezetimibe-mediated therapeutic effects.
Results:
PRDM5 was identified as a pivotal ASCVD risk gene, with significantly upregulated expression in monocytes and plaque tissues from patients. Mechanistically, PRDM5 directly binds the ASK1 promoter to trigger ASK1/JNK/NF-κB signaling, aggravating macrophage lipid overloading, inflammatory activation and apoptosis, and further inducing endothelial dysfunction through paracrine mediators. Ezetimibe suppresses the transcriptional activity of PRDM5.
Conclusion:
PRDM5 serves as a common susceptibility gene for ASCVD and facilitates macrophage pathogenic phenotypes via the ASK1/JNK/NF-κB cascade.
Insights
PR domain zinc finger protein 5 (PRDM5) is a key genetic factor in atherosclerotic cardiovascular disease (ASCVD). It drives macrophage dysfunction and inflammation, contributing to systemic lesions, but can be targeted by ezetimibe.
Area of Science:
- Cardiovascular Genetics
- Molecular Biology
- Immunology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) exhibits shared genetic susceptibility across diverse vascular lesions.
- Identifying common pathogenic factors for multi-territorial atherosclerosis is crucial.
- PR domain zinc finger protein 5 (PRDM5) is hypothesized to regulate systemic atherosclerotic lesions by modulating monocyte-macrophage function.
Purpose of the Study:
- To investigate PR domain zinc finger protein 5 (PRDM5) as a shared genetic regulator in atherosclerotic cardiovascular disease (ASCVD).
- To elucidate the molecular mechanisms by which PRDM5 contributes to systemic atherosclerosis.
- To evaluate the therapeutic potential of ezetimibe in targeting PRDM5-mediated pathways.
Main Methods:
- Utilized multi-trait genome-wide association studies (GWAS) and genomic structural equation modeling (Genomic SEM) to identify shared ASCVD risk loci.
- Performed transcriptome-wide association study (TWAS) in CD14+ monocytes to prioritize candidate genes.
- Conducted cellular functional assays, ChIP-qPCR, dual-luciferase reporter assays, and molecular docking to determine downstream signaling and ezetimibe effects.
Main Results:
- PRDM5 was identified as a pivotal ASCVD risk gene with significantly upregulated expression in patient monocytes and atherosclerotic plaques.
- PRDM5 directly binds the ASK1 promoter, activating the ASK1/JNK/NF-κB signaling pathway.
- This activation exacerbates macrophage lipid accumulation, inflammation, apoptosis, and endothelial dysfunction; ezetimibe was found to suppress PRDM5 transcriptional activity.
Conclusions:
- PRDM5 acts as a common susceptibility gene for atherosclerotic cardiovascular disease (ASCVD).
- PRDM5 facilitates pathogenic macrophage phenotypes through the ASK1/JNK/NF-κB cascade.
- Ezetimibe demonstrates potential for therapeutic intervention by inhibiting PRDM5 activity.
Related Concept Videos
Inflammation
Regulation of the Unfolded Protein Response
Abnormal Proliferation
